JP2023519851A5 - - Google Patents
Info
- Publication number
- JP2023519851A5 JP2023519851A5 JP2022558065A JP2022558065A JP2023519851A5 JP 2023519851 A5 JP2023519851 A5 JP 2023519851A5 JP 2022558065 A JP2022558065 A JP 2022558065A JP 2022558065 A JP2022558065 A JP 2022558065A JP 2023519851 A5 JP2023519851 A5 JP 2023519851A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025135194A JP2025161873A (ja) | 2020-03-23 | 2025-08-14 | 武装免疫細胞を産生する際に使用するための二重特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993080P | 2020-03-23 | 2020-03-23 | |
| US62/993,080 | 2020-03-23 | ||
| PCT/US2021/023655 WO2021195067A1 (en) | 2020-03-23 | 2021-03-23 | Bi-specific antibodies for use in producing armed immune cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025135194A Division JP2025161873A (ja) | 2020-03-23 | 2025-08-14 | 武装免疫細胞を産生する際に使用するための二重特異性抗体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023519851A JP2023519851A (ja) | 2023-05-15 |
| JP2023519851A5 true JP2023519851A5 (https=) | 2024-04-02 |
| JPWO2021195067A5 JPWO2021195067A5 (https=) | 2024-04-02 |
| JP7729833B2 JP7729833B2 (ja) | 2025-08-26 |
Family
ID=77892613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022558065A Active JP7729833B2 (ja) | 2020-03-23 | 2021-03-23 | 武装免疫細胞を産生する際に使用するための二重特異性抗体 |
| JP2025135194A Pending JP2025161873A (ja) | 2020-03-23 | 2025-08-14 | 武装免疫細胞を産生する際に使用するための二重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025135194A Pending JP2025161873A (ja) | 2020-03-23 | 2025-08-14 | 武装免疫細胞を産生する際に使用するための二重特異性抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240209084A1 (https=) |
| EP (1) | EP4126954A4 (https=) |
| JP (2) | JP7729833B2 (https=) |
| CN (1) | CN115551890A (https=) |
| AU (1) | AU2021244375A1 (https=) |
| IL (1) | IL296566A (https=) |
| TW (1) | TWI904147B (https=) |
| WO (1) | WO2021195067A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| TW202323295A (zh) * | 2021-08-11 | 2023-06-16 | 賽昂生醫股份有限公司 | 用於產生武裝免疫細胞的方法 |
| WO2023143478A1 (en) * | 2022-01-27 | 2023-08-03 | Crown Bioscience Inc. | Novel anti-cd4 and anti-pd-l1 bispecific antibodies |
| CN118005806B (zh) * | 2024-02-08 | 2026-01-30 | 北京市眼科研究所 | 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用 |
| CN121248779A (zh) * | 2024-06-25 | 2026-01-02 | 冕屹立生物技术(上海)有限公司 | 靶向人cd3分子的抗体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030108548A1 (en) * | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| US9611325B2 (en) * | 2014-07-21 | 2017-04-04 | Wuhan Yzy Biopharma Co., Ltd. | Construction and application of bispecific antibody HER2xCD3 |
| US10519248B2 (en) * | 2014-07-25 | 2019-12-31 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| RS60739B1 (sr) * | 2014-11-17 | 2020-09-30 | Regeneron Pharma | Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela |
| CN104829725A (zh) * | 2015-01-21 | 2015-08-12 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体cd133×cd3的构建及应用 |
| US11649435B2 (en) * | 2015-08-28 | 2023-05-16 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| US11702477B2 (en) * | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| WO2018049261A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| WO2018177371A1 (en) * | 2017-03-29 | 2018-10-04 | Taipei Medical University | Antigen-specific t cells and uses thereof |
| EP3802595A1 (en) * | 2018-06-07 | 2021-04-14 | OncoOne Research & Development GmbH | Anti-oxmif/anti-cd3 antibody for cancer treatment |
-
2021
- 2021-03-23 EP EP21774346.7A patent/EP4126954A4/en active Pending
- 2021-03-23 WO PCT/US2021/023655 patent/WO2021195067A1/en not_active Ceased
- 2021-03-23 IL IL296566A patent/IL296566A/en unknown
- 2021-03-23 AU AU2021244375A patent/AU2021244375A1/en active Pending
- 2021-03-23 CN CN202180029464.3A patent/CN115551890A/zh active Pending
- 2021-03-23 JP JP2022558065A patent/JP7729833B2/ja active Active
- 2021-03-23 TW TW110110483A patent/TWI904147B/zh active
- 2021-03-23 US US17/913,775 patent/US20240209084A1/en active Pending
-
2025
- 2025-08-14 JP JP2025135194A patent/JP2025161873A/ja active Pending